Anyone interested in NeoGenomics, Inc. (NASDAQ:NEO) should probably be aware that the Senior VP & Chief Accounting Officer, Gregory Aunan, recently divested US$321k worth of shares in the company, at an average price of US$16.07 each. In particular, we note that the sale equated to a 80% reduction in their position size, which doesn’t exactly instill confidence.
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
NeoGenomics Insider Transactions Over The Last Year
Notably, that recent sale by Gregory Aunan is the biggest insider sale of NeoGenomics shares that we’ve seen in the last year. That means that an insider was selling shares at slightly below the current price (US$16.53). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. However, while insider selling is sometimes discouraging, it’s only a weak signal. We note that the biggest single sale was 80% of Gregory Aunan’s holding.
NeoGenomics insiders didn’t buy any shares over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
See our latest analysis for NeoGenomics
For those who like to find hidden gems this freelist of small cap companies with recent insider purchasing, could be just the ticket.
Insider Ownership
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 2.1% of NeoGenomics shares, worth about US$45m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
So What Does This Data Suggest About NeoGenomics Insiders?
Insiders haven’t bought NeoGenomics stock in the last three months, but there was some selling. And there weren’t any purchases to give us comfort, over the last year. Insider ownership isn’t particularly high, so this analysis makes us cautious about the company. We’d practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it’s also worthwhile knowing the risks facing this company. In terms of investment risks, we’ve identified 2 warning signswith NeoGenomics and understanding these should be part of your investment process.
Of course NeoGenomics may not be the best stock to buy. So you may wish to see this freecollection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Valuation is complex, but we’re here to simplify it.
Discover if NeoGenomics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content?Get in touchwith us directly.Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:NEO
NeoGenomics
Operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
Adequate balance sheet with very low risk.
Similar Companies
Market Insights
What Korea’s market says about your index fundMitchell Lawler
What does frontier-beating open sector might be its most misreadMitchell Lawler
Advertisement
Weekly Picks
davidlsanderon Optimi Health·9 days ago
OPTH: A licensed manufacturer already selling MDMA while peers still wait on trials
Fair Value:US$1261.0% undervalued
16followersusers have followed this narrative
·0commentsusers have commented on this narrative
·2likesusers have liked this narrative
FU
FundamentalFlowon Vertiv Holdings Co·9 days ago
The Short and Long Term Compounder of Liquid Cooling industry.
John_Ericon SPX Technologies·5 days ago
I Fell in Love With a Data-Center Cooling Stock. Then I Opened the Filings.
tripledubon GQG Partners·3 months ago
The Cheap Genius Problem
RecentlyUpdated Narratives
Agricolaon Luca Mining·about 3 hours ago
A Case for Luca Mining Corp reaching (Bull Case) CAD $9.00 – 12.00 by Early 2031
AstrisCorporateAdvisoryon Japan Elevator Service HoldingsLtd·about 4 hours ago
Sales team expansion to support growth
AstrisCorporateAdvisoryon Sanyo Trading·about 4 hours ago
Delivering steady performance
Popular Narratives
oscargarciaon NVIDIA·2 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
CubanEroson Microsoft·about 1 month ago
A wonderful business at reasonable price.
KiwiInveston Amazon.com·3 months ago
